Arca
Skip to content
Tools
Tools

TPBG: Trophoblast glycoprotein

May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization. .

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on TPBG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate 2
  • Other 1

Approved0

    Phase 30

      Phase 22

      • Naptumomab estafenatox
      • Anatumomab mafenatox

      Phase 11

      • PF-06263507

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Naptumomab estafenatoxPhase 2NeoTX Therapeutics Ltd.Antibody-drug conjugateOtherTrophoblast glycoprotein other1
      Anatumomab mafenatoxPhase 2—Antibody-drug conjugateBinding agentTrophoblast glycoprotein other0
      PF-06263507Phase 1—OtherBinding agentTrophoblast glycoprotein binding agent0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 1 in all, from ClinicalTrials.gov.
      TrialDrugPhaseStatusLead sponsorFirst posted
      Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Naptumomab estafenatoxPhase 1Active, not recruitingNeoTX Therapeutics Ltd.Jun 12, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Abnormality of the skeletal system0.46
      • Placenta praevia0.31
      • Liver disorder0.30
      • Ovarian neoplasm0.25
      • Nephritis0.18
      • Nephropathy0.18
      • Preeclampsia0.14
      • Amblyopia0.14
      • Ovarian dysfunction0.13
      • Color vision disorder0.11
      • Adolescent idiopathic scoliosis0.10

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712934, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q13641, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.